【摘要】：目的:系統(tǒng)評(píng)價(jià)選擇性5-羥色胺再攝取抑制劑(SSRI)用于行體外受精聯(lián)合胚胎移植術(shù)的抑郁癥婦女的妊娠安全性,為臨床提供循證參考。方法:計(jì)算機(jī)檢索PubMed、EMBase、Cochrane圖書館、Medline、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)、相關(guān)期刊論文、中文科技期刊數(shù)據(jù)庫(kù)和萬(wàn)方數(shù)據(jù)庫(kù),納入SSRI(試驗(yàn)組)對(duì)比不接受藥物或僅使用安慰劑(對(duì)照組)用于行體外受精聯(lián)合胚胎移植術(shù)的抑郁癥婦女的試驗(yàn),提取資料并評(píng)價(jià)質(zhì)量后,采用Rev Man 5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:共納入4項(xiàng)研究,合計(jì)2 122例患者。Meta分析結(jié)果顯示,兩組患者流產(chǎn)率[RR=0.90,95%CI(0.61,1.35),P=0.62]、受孕率[RR=1.03,95%CI(0.73,1.45),P=0.87]和胎兒出生率[RR=1.03,95%CI(0.65,1.63),P=0.91]比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論:SSRI用于行體外受精聯(lián)合胚胎移植術(shù)的抑郁癥婦女不會(huì)增加流產(chǎn)率,對(duì)受孕率和胎兒出生率亦無(wú)顯著影響。
[Abstract]:Objective: to systematically evaluate the pregnancy safety of depressed women undergoing in vitro fertilisation and embryo transfer with selective serotonin reuptake inhibitor (SSRI), and to provide evidence-based reference for clinical practice. Methods: PubMed,EMBase,Cochrane Library, Medline, Chinese Biomedical Literature Database, Chinese Journal full-text Database, Chinese Sci-tech Journal Database and Wanfang Database were searched by computer. SSRI (experimental group) was used to compare depressed women who did not receive drugs or only placebo (control group). After extracting the data and evaluating the quality, Meta analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 2122 patients were included in four studies. Meta-analysis showed that there was no significant difference in abortion rate [RR=0.90,95%CI (0.61, 1.35), P 鈮，

本文編號(hào)：2510252